Enzolytics Inc (ENZC)

[foxi]

To end the day here's some cherrypicked DD from a search for "immb audit enzc" on ihub. I was curious what people had said before since I wasn't trading ENZC before April 2021. Happy Labor Day to all and may this ticker see green on Tuesday! :)



(All posts are from 2021)

3/10 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162481459

IMMB still holds the rights to the “licensed manufacturing” of the ImmunH(ITV1-4). Why? You ask. It’s to cover the Approval in either governing body, whether it be here or in Europe.

3/11 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162485825

Not one person can prove(with an SEC document) that Enzolytics Inc. owns the patent on the ImmunH(ITV1-4). Enzolytics has a license agreement to manufacturer the material but that is it.

Until proven otherwise, "The Zhabilov Trust" OWNS the patent has and always will.

Which means that the The Zhabilov Trust can sell ImmunH(ITV1-4) to the highest bidder.

Leaving both of my investments in IMMB and ENZC high and dry.

3/11 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162496741

Why would the Zhabilov Trust sell the patent when they can just make multiple license agreements?

Their current EXCLUSIVE licensing agreement with Immunotech (which was transferred completely into ENZC) has already paid out $775,000 to Zhabilov and $775,000 to Ara with 5% royalties being split between the two from the worldwide sales.

I'm sure the sub-license agreement to the subsidiary IMMB BG is being dissolved right now due to the notice of default being filed in Sofia (I'm thinking that Dimitar is either being strong-armed out of the deal or bought out by making his restricted shares into unrestricted so he can sell on the open market.) And there is likely a new sub-license agreement being made with the new subsidiary IMPL so they can commercialize in Europe (which would be sub-license to the Exclusive Licensing Agreement with Enzolytics).

Harry and the Zhabilov trust will be making money with ENZC through royalties from the ELA &&& through the increased share value between the hundreds of millions of shares that they own collectively (both common and preferred).

IMMB is completely out of the picture here and will not be receiving anything so I don't know why anyone would own shares there.

3/11 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162498099

IMMB is dead as a ticker. All of its worth was transferred into ENZC.

Pages 9 & 10 in the annual report go over this.

IMMB can burn to the ground because it owns nothing after the asset purchase was finalized. Harry doesn't care about something that is worth nothing now.

3/12 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162510937

What did ENZC, or at the time Eco-Petroleum Solutions, pay IMMB for the transfer of assets? If there was a Share Exchange Agreement, how many shares were "exchanged?" Meanwhile, Immunotech Laboratories BG states on it's website that IMMB owns 49%, not ENZC...

Immunotechlaboratories BG

Thus, still a matter of controversy.

Assets may not be simply be transfered without consideration. Documentation of such consideration is still murky, so it is difficult to conclude that IMMB is merely a "dead ticker" or an empty shell, or that anything was ever finalized. But if you have a specific reference, please to share. Otherwise, with respect to ITV-1, perhaps ENZC is the "dead ticker."

3/12 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162511369

IMMB BG is a Subsidiary of IMMB which was the parent company who had the Exclusive License Agreement. Harry the majority owner of IMMB.

IMMB BG has a Sub-license agreement with Immunotech (which is now transferred to ENZC) and is how Harry is able to go after all of the clinical trials data from IMMB BG in Sofia which was transferred through the asset purchase agreement.

ENZC "paid" common stock to Immunotech and paid off debts owed by Immunotech according to the Annual Filing

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.

Additionally, Dimitar is shown as receiving 170,000,000 common restricted shares on March 23, 2018 - as well as a list of other people likely associated with the IMMB BG subsidiary that have a number of shares being received around the same time in March of 2018. All of their names appear to be Bulgarian.

3/12 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162515082

There is definitely an ongoing dust up between Dimitar and Harry. You can also check the Immunotech BG Facebook page. Dimitar is clearly not happy.

As to what you quote from the filings:

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.

The problem is that there was never any follow on filing indicating the purchase agreement actually came to fruition. But assuming it did come to fruition, then $IMMB holds some number of shares in $ENZC and a note receivable. Stock paid directly to Dimitar or others with Bulgarian names is different than stock that would belong to the shareholders of $IMMB common stock, so it's hard to characterize $IMMB as a dead ticker since it clearly owns something, whether it be IP and 49% interest in Immunotech BG, or a note receivable and $ENZC common stock. Unfortunately, there is an incomplete accounting of this deal if it did, in fact, go through and this is complicated by Harry serving as CEO of $IMMB and CSO of $ENZC at the same time.

And this from ENZC on April 4 https://www.otcmarkets.com/otcapi/company/financial-report/278146/content

The investment representing 49% ownership of IMMB BG is reflected in the Investment in Subsidiaries on the Holding Company balance sheet. The investment is carried at cost. With the cancelation in February 2021 of the Sub-License agreement and termination of all other contractual ties to IMMB BG, the Company will begin reviewing the value of the investment at the end of future reporting periods and write it down to Market value, which may be zero as IMMB BG appears to have no operations, Intellectual Property or other assets of value. IMMB BG’s sub-license and distribution agreement from the Company has been cancelled. IMMB BG has never had any rights to the Intellectual Property or Manufacturing rights to the treatment, only a distribution and licensing agreement for certain territories. The President of IMMB BG is not and has never been an officer of the Company or IMMB from which the ITV-1 treatment and 49% ownership of IMMB BG was acquired.

With the ongoing lawsuit and its claims happening after that.